Month: October 2022

Heterogeneous nuclear ribonucleoprotein A2/B1 as a novel biomarker in elderly patients for the prediction of postoperative neurocognitive dysfunction: A prospective nested case-control study

Background and objectivePostoperative neurocognitive dysfunction (PND) occurs in up to 54% of older patients, giving rise to the heavy psychological and economic burdens to patients and society. To date, the development of PND biomarkers remains a challenge. Heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2/B1) is an RNA-binding protein whose prion-like structure is prone to mutation and hence […]

Published on October 21, 2022

Reevaluating Early Mammograms for Women with Family History of Breast Cancer

Like a detective reexamining a case, a recent study is causing medical experts to reconsider the timing of mammograms for women who have a family history of breast cancer. The study found that starting mammograms at a later age may be just as effective in detecting breast cancer as starting them earlier. It’s like changing […]

Published on October 21, 2022

Pfizer Will Charge $110-$130 For COVID-19 Shot

Picture this: You go to a carnival and snag a free balloon from the booth. But to ride the Ferris wheel, you’ve got to pull out some cash. That’s kind of what Pfizer is doing with its COVID-19 vaccine. Once the U.S. government stops buying doses, Pfizer will start charging $110 to $130 per shot […]

Published on October 21, 2022